Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Condition: Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Sponsor: G1 Therapeutics Inc

A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting. This is an exploratory Phase 2, multicenter, open-label study evaluating the safety and efficacy of trilaciclib administered with sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic TNBC who received at least 2 prior treatments, at least 1 in the metastatic setting.


Go To Trial Homepage